Did Medicare Start Paying for CBD? Not Quite — Here's What Actually Happened

For Seniors

If you have seen a headline like "Free CBD Through Medicare" or "Seniors Can Get $500 in CBD," you are not imagining it. Something real did happen. But most of what has been written about it is wrong in ways that matter, and a few of the write-ups read like they were built to sell you something.

Here is the plain version, taken straight from the Centers for Medicare & Medicaid Services — the federal agency that runs Medicare.

What CMS actually created

It is called the Substance Access Beneficiary Engagement Incentive. CMS describes it as an optional add-on that lets participating organizations "consult with eligible beneficiaries about the possible use of eligible hemp products to improve symptom control."

In practice, that means a doctor's organization that is already part of one of three Medicare test programs may choose to offer hemp products to some of its patients, and may spend up to $500 per patient per year doing it.

The three programs are the ACO REACH Model and the Enhancing Oncology Model, both of which could begin offering it on April 1, 2026, and the Long-term Enhanced ACO Design Model, which becomes eligible on January 1, 2027.

Who can offer it, and who can receive it

An organization can only offer this if it is already in one of those three Medicare models, chooses to opt in for the year, files a detailed implementation plan with CMS describing the exact products and dosing, and gets approved. CMS can reject or suspend any of them.

On the patient side, you have to already be assigned to one of those participating organizations. CMS lists the general criteria as:

• Age 18 or older — note that this is not a seniors-only program
• Not meeting the model's frailty exclusion
• Not having certain disqualifying conditions, which each model spells out separately
• Not pregnant or breastfeeding

On top of that, a physician has to decide it is appropriate for you and document a real conversation about it — the potential benefits and risks, your own goals and preferences, and a review of everything else you are taking and how it might interact.

That last requirement is worth sitting with. Even the federal government, setting this up, made a medication review mandatory. It is the same conversation we point people toward before they try any CBD product, and it is the right one.

What counts as an "eligible hemp product"

CMS drew the line fairly tightly. Eligible products must be federally legal hemp, containing no more than 0.3% delta-9 THC. Specifically excluded:

• Anything inhalable — no smokable flower, no vapes
• Anything taken by mouth with more than 3 mg per serving of THC compounds, including delta-8, delta-10, and THCA
• Any cannabinoid that the hemp plant cannot actually produce on its own — which rules out the lab-made novelty compounds

Products also have to come from a legally compliant, high-quality farm under the 2018 Farm Bill, and be tested by a third-party lab for accurate cannabinoid content and for contaminants and microbial hazards, with negative results.

And the products must comply with state and local law — which, in Kansas, is a meaningful catch. More on that below.

What this means in Kansas

Kansas has its own rules on top of the federal ones. Kansas caps a finished hemp product at 0.3% total THC, and counts every form of THC toward that number rather than delta-9 alone — a stricter measurement than the federal standard, at the same number. Kansas also bans certain categories outright regardless of THC content, inhalables among them, which the CMS rules exclude anyway.

Because the CMS rules require compliance with state and local law on top of the federal standard, a Kansas patient in one of these programs would be looking at products that meet the Kansas standard, not just the federal one.

There is one more wrinkle. CMS said plainly that if the legal limits change — and it named Section 781 of the FY2026 Agriculture Appropriations Act specifically — it will adjust its definition to match. That is the federal hemp rule taking effect on November 12, 2026, which moves the whole country from a delta-9-only measurement to a total-THC measurement and adds a 0.4 mg per-container cap. We wrote about that separately: the November 12, 2026 hemp law, explained.

In other words, this program's product rules are already scheduled to move. Anything you read about it that was written before that rule was on the radar is working from an older picture.

Three things the headlines get wrong

• "Medicare is paying for CBD." It is not. Participating organizations pay for the products themselves, out of their own budgets.
• "Seniors can get $500 in free CBD." The eligibility floor is 18, not 65. It reaches Medicare beneficiaries, who do skew older — but it was not written as a seniors' benefit, and calling it one oversells it.
• "Here's how to sign up." There is no sign-up. You cannot enroll, apply, or opt in. Either the organization your care already runs through is part of one of three specific Medicare models and chose to do this, or it is not.

You also cannot buy CBD at a store and get it covered. CMS addressed that directly: organizations "cannot instruct beneficiaries to purchase retail products and submit receipts for reimbursement." The products have to be furnished to you by a qualified physician affiliated with that organization.

Where K61 stands on this

We are not part of this program, and we want to be straightforward about why we are telling you about it anyway.

CMS built in rules that specifically prohibit organizations from marketing the program to attract patients, and prohibit any arrangement that pays an organization to favor one manufacturer or seller over another. Those are sensible rules. They also mean that any CBD company implying it is "Medicare approved" is telling you something that is not true, and you should treat that company's other claims with the same suspicion.

If you are in one of these programs, the products are coming from your doctor, not from a website. If you are not, this changes nothing about what you can buy — and nobody, including us, can get you into it.

If you are curious, ask your care team

The only people who can tell you whether this applies to you are the people who run your care. A short, specific question works better than a general one:

• "Is this practice part of ACO REACH, the Enhancing Oncology Model, or the LEAD model?"
• "If it is, did we opt into the Substance Access incentive this year?"
• "If not, is CBD something you would want me to avoid given what I'm currently taking?"

That third question is the useful one regardless of the answers to the first two. The medication review CMS made mandatory inside this program is worth having outside of it too.